JP2019513828A - 改善された薬物動態を有するイソフラボノイド組成物 - Google Patents

改善された薬物動態を有するイソフラボノイド組成物 Download PDF

Info

Publication number
JP2019513828A
JP2019513828A JP2019503599A JP2019503599A JP2019513828A JP 2019513828 A JP2019513828 A JP 2019513828A JP 2019503599 A JP2019503599 A JP 2019503599A JP 2019503599 A JP2019503599 A JP 2019503599A JP 2019513828 A JP2019513828 A JP 2019513828A
Authority
JP
Japan
Prior art keywords
formula
compound
rectal administration
formulation
suppository
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019503599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513828A5 (enExample
Inventor
ケリー グレイアム
ケリー グレイアム
ポーター ケイト
ポーター ケイト
Original Assignee
ノクソファーム リミティド
ノクソファーム リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2016/050674 external-priority patent/WO2017173474A1/en
Application filed by ノクソファーム リミティド, ノクソファーム リミティド filed Critical ノクソファーム リミティド
Publication of JP2019513828A publication Critical patent/JP2019513828A/ja
Publication of JP2019513828A5 publication Critical patent/JP2019513828A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019503599A 2016-04-06 2017-04-06 改善された薬物動態を有するイソフラボノイド組成物 Ceased JP2019513828A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
US62/318,946 2016-04-06
AUPCT/AU2016/050674 2016-07-28
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment
US201762480692P 2017-04-03 2017-04-03
US62/480,692 2017-04-03
PCT/AU2017/050301 WO2017173498A1 (en) 2016-04-06 2017-04-06 Isoflavonoid composition with improved pharmacokinetics

Publications (2)

Publication Number Publication Date
JP2019513828A true JP2019513828A (ja) 2019-05-30
JP2019513828A5 JP2019513828A5 (enExample) 2020-05-21

Family

ID=60000544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503599A Ceased JP2019513828A (ja) 2016-04-06 2017-04-06 改善された薬物動態を有するイソフラボノイド組成物

Country Status (6)

Country Link
US (1) US11559510B2 (enExample)
EP (2) EP3439644B1 (enExample)
JP (1) JP2019513828A (enExample)
AU (1) AU2017247008B2 (enExample)
CA (1) CA3058503A1 (enExample)
WO (1) WO2017173498A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3439643A4 (en) * 2016-04-06 2019-12-11 Noxopharm Limited TARGETED ACTIVE SUBSTANCE
CA3058492A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
WO2017173498A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
BR112021026559A2 (pt) * 2019-07-17 2022-02-15 Noxopharm Ltd Terapia imuno-oncológica usando compostos isoflavona
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676314B2 (ja) * 1985-09-30 1994-09-28 花王株式会社 坐剤基剤及び坐剤
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
US20090233999A1 (en) 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
CN1646119A (zh) 2002-04-09 2005-07-27 诺沃根研究有限公司 涉及异黄－3－烯和异黄烷结构的治疗方法和组合物
BR0313182A (pt) * 2002-07-24 2007-07-24 Childrens Hosp Medical Center composições e produtos contendo equol enantiomérico
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2002952453A0 (en) 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
CA2538570A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050154452A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7434690B2 (en) 2004-04-30 2008-10-14 Cutispharma, Inc. Container and method for the preparation, storage and dispensing of compounded suppositories
ATE532777T1 (de) 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
EP2436680B1 (en) 2004-09-21 2016-05-18 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
DE102005009515A1 (de) 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
CN101203219B (zh) 2005-03-24 2011-06-15 诺沃根研究控股有限公司 消炎用药程式
WO2007035515A2 (en) 2005-09-15 2007-03-29 Umd, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
US20070196381A1 (en) 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
US20100152284A1 (en) * 2006-10-30 2010-06-17 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
JP2010531811A (ja) * 2007-06-29 2010-09-30 ノボゲン リサーチ ピーティーワイ リミテッド ２−置換イソフラボノイド化合物、医薬及び使用
EP2334296A4 (en) 2008-08-29 2012-04-25 Novogen Res Pty Ltd IMMUNOMODULATING ACTIVITIES
EP2365955B1 (en) 2008-11-14 2014-12-31 Heartlink Limited Aryl di-substituted propenone compounds
KR20110004525A (ko) * 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
WO2013056217A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
BR112015023256A2 (pt) 2013-03-13 2017-07-18 Oncoceutics Inc terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.
US20150126597A1 (en) 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
MY195739A (en) 2014-02-07 2023-02-08 Novogen ltd Functionalised Benzopyran Compounds and use Thereof
SMT202200285T1 (it) 2014-08-11 2022-09-14 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016192680A1 (en) * 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
PL3334431T3 (pl) 2015-08-11 2020-03-31 Novartis Ag 5-bromo-2,6-di-(1H-pirazol-1-ilo)pirymidyno-4-amina do zastosowania w leczeniu nowotworu złośliwego
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
SG11201808777UA (en) 2016-04-06 2018-11-29 Noxopharm Ltd Improvements in cancer treatment
WO2017173498A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
US20190117620A1 (en) 2016-04-22 2019-04-25 Noxopharm Limited Chemotherapy improvements
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
WO2019240872A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
EP3806846A1 (en) 2018-06-15 2021-04-21 Board of Regents, The University of Texas System Methods of treating and preventing breast cancer with s-equol
WO2020051644A1 (en) 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT03041285", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6021011776, 31 January 2017 (2017-01-31), ISSN: 0004656810 *
DEFINITION OF IDRONOXIL SUPPOSITORY NOX66, NCI DRUG DICTIONARY [ONLINE], JPN6021011779, 25 March 2021 (2021-03-25), ISSN: 0004476623 *
医療, vol. 29, no. 6, JPN6021011781, 1975, pages 94 - 103, ISSN: 0004656812 *
日消外会誌, vol. 15, no. 1, JPN6021011777, 1982, pages 78 - 85, ISSN: 0004656811 *
油化学, vol. 19, no. 8, JPN6021011778, 1970, pages 722 - 733, ISSN: 0004656813 *

Also Published As

Publication number Publication date
EP3439644A1 (en) 2019-02-13
AU2017247008B2 (en) 2022-04-07
EP3439644B1 (en) 2022-01-12
AU2017247008A1 (en) 2018-11-01
WO2017173498A1 (en) 2017-10-12
EP4005567A1 (en) 2022-06-01
US11559510B2 (en) 2023-01-24
EP3439644A4 (en) 2019-10-30
US20190117618A1 (en) 2019-04-25
CA3058503A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
US12403114B2 (en) Cannabinoid acid ester compositions and uses thereof
JP7193591B2 (ja) 化学療法の改善
JP2019513828A (ja) 改善された薬物動態を有するイソフラボノイド組成物
KR20070027575A (ko) 면역억제제 또는 항신생물제 중 하나 이상 및 다중불포화지방산을 함유하는 약제 조성물
CN101583606A (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
TW201840309A (zh) 治療及/或預防癌症用組合物
US20210338576A1 (en) Cancer treatment
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
WO2025093572A1 (en) Solid dispersion compositions and uses thereof
HK40006250A (en) Improvements in cancer treatment
JP2019513827A (ja) 標的化薬物送達
HK1178458A (en) Therapeutic agent for liver cancer
HK1138797A (zh) 肝癌治疗剂
CN101610771A (zh) 肝癌治疗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220407

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220419

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20231128